Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Impedimed Limited ( (AU:IPD) ).
ImpediMed Limited announced a change in the director’s interest notice, involving Ms. Christine Emmanuel-Donnelly. The change reflects the issuance of 474,084 ordinary shares to IDEAHL Pty Ltd, a trust where Ms. Emmanuel-Donnelly is a director and beneficiary, as part of her director fees for the quarter ended June 30, 2025. This move indicates a strategic decision to compensate directors through equity, potentially aligning their interests with those of shareholders and impacting the company’s financial structure.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, specializing in non-invasive medical devices for the measurement of fluid status and body composition. The company’s primary products include bioimpedance spectroscopy devices used for the assessment and monitoring of lymphedema, heart failure, and other fluid-related medical conditions.
Average Trading Volume: 2,702,662
Technical Sentiment Signal: Sell
Current Market Cap: A$103.4M
See more insights into IPD stock on TipRanks’ Stock Analysis page.